Cargando…

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review

Platinum (Pt) derivatives such as cisplatin and carboplatin are the class of drugs with proven activity against triple-negative breast cancer (TNBC). This is due to the ability of Pt compounds to interfere with the DNA repair mechanisms of the neoplastic cells. Taxanes have been efficacious against...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Hao, Ma, Dandan, Tan, Xuanni, Yan, Wenting, Wu, Xiujuan, He, Cheng, Zhong, Ling, Zhang, Yan, Yu, Bingjie, Zhang, Yi, Qi, Xiaowei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685522/ https://www.ncbi.nlm.nih.gov/pubmed/34938186 http://dx.doi.org/10.3389/fphar.2021.770663

Ejemplares similares

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial
por: Yan, Wenting, et al.
Publicado: (2022)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2018)

Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
por: Li, Zhen-Yu, et al.
Publicado: (2020)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
por: Kianersi, Shirin, et al.
Publicado: (2023)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zhang, Zilin, et al.
Publicado: (2021)

A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer
por: Feng, Wuna, et al.
Publicado: (2021)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

The Effect of Neoadjuvant vs Adjuvant Chemotherapy on Final Outcome of Patients with Triple Negative Breast Cancer
por: Dabbagh, Najmeh, et al.
Publicado: (2022)

Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence
por: Fridley, Brooke L., et al.
Publicado: (2016)

Nanocarriers containing platinum compounds for combination chemotherapy
por: Fang, Guihua, et al.
Publicado: (2022)

Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2020)

A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer
por: Zhang, Dan, et al.
Publicado: (2019)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
por: Liu, Yixin, et al.
Publicado: (2019)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival
por: Matsuo, Koji, et al.
Publicado: (2019)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2019)

Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I–III HER2‐Positive Breast Cancer: A Phase II Clinical Trial
por: Xuhong, Juncheng, et al.
Publicado: (2020)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

Platinum‐based chemotherapy for early triple‐negative breast cancer
por: Mason, Sofia RE, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
por: Molassiotis, Alex, et al.
Publicado: (2019)

A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
por: Du, Yueyao, et al.
Publicado: (2018)

Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis
por: Li, Junjie, et al.
Publicado: (2022)

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012)

The role of taxanes in triple-negative breast cancer: literature review
por: Mustacchi, Giorgio, et al.
Publicado: (2015)

Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer
por: Takeda, Risa, et al.
Publicado: (2015)

Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
por: Patil, Vijay M, et al.
Publicado: (2014)

Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy
por: Liu, Jia-Si, et al.
Publicado: (2023)

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
por: Heinzelmann-Schwarz, Viola, et al.
Publicado: (2020)

Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
por: Xia, Lin-Yu, et al.
Publicado: (2020)

The role of taxanes in triple-negative breast cancer: literature review [Corrigendum]
Publicado: (2015)

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer
por: Chen, Yimeng, et al.
Publicado: (2023)

Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer
por: Liao, Gaoming, et al.
Publicado: (2021)

Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Wenfeng, et al.
Publicado: (2020)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sl8ob4i132i5r617m6n6l9q9vs